Wedbush Issues Negative Forecast for Generation Bio Earnings

Generation Bio Co. (NASDAQ:GBIO) – Wedbush reduced their Q2 2025 EPS estimates for shares of Generation Bio in a note issued to investors on Wednesday, May 7th. Wedbush analyst D. Nierengarten now expects that the company will earn ($0.29) per share for the quarter, down from their prior estimate of ($0.23). Wedbush currently has a “Outperform” rating and a $5.00 target price on the stock. The consensus estimate for Generation Bio’s current full-year earnings is ($1.75) per share. Wedbush also issued estimates for Generation Bio’s Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.10) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.80) EPS, FY2028 earnings at ($0.83) EPS and FY2029 earnings at ($0.75) EPS.

Generation Bio (NASDAQ:GBIO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.03. The business had revenue of $8.72 million for the quarter, compared to analysts’ expectations of $1.70 million. Generation Bio had a negative return on equity of 104.85% and a negative net margin of 782.86%.

Other research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Generation Bio in a report on Thursday. Canaccord Genuity Group restated a “buy” rating and set a $9.00 price objective on shares of Generation Bio in a research note on Monday, March 17th.

Generation Bio Stock Performance

Shares of GBIO opened at $0.35 on Monday. The firm’s 50-day simple moving average is $0.43 and its 200 day simple moving average is $0.92. The firm has a market cap of $23.52 million, a P/E ratio of -0.16 and a beta of 2.76. Generation Bio has a 52 week low of $0.32 and a 52 week high of $4.34.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. acquired a new stake in Generation Bio in the fourth quarter valued at about $2,398,000. Renaissance Technologies LLC grew its holdings in shares of Generation Bio by 62.0% during the fourth quarter. Renaissance Technologies LLC now owns 962,959 shares of the company’s stock worth $1,021,000 after purchasing an additional 368,659 shares during the last quarter. Deutsche Bank AG boosted its position in Generation Bio by 688.7% during the 4th quarter. Deutsche Bank AG now owns 184,173 shares of the company’s stock worth $195,000 after buying an additional 160,822 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Generation Bio by 74.9% during the fourth quarter. JPMorgan Chase & Co. now owns 297,705 shares of the company’s stock valued at $316,000 after acquiring an additional 127,513 shares during the last quarter. Finally, EWA LLC bought a new stake in shares of Generation Bio in the first quarter worth $38,000. 95.22% of the stock is owned by institutional investors.

About Generation Bio

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.